Actinium Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $41.46M
- P/E (TTM)
- 3.7
- Dividend yield
- –
About Actinium Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer treatment. The company combines tumor biology and radiochemistry to advance radiopharmaceutical therapeutics for solid tumors and hematologic malignancies. Its pipeline includes solid tumor product candidates such as ATNM-400, an Ac-225 antibody radioconjugate targeting a non-PSMA antigen across indications such as prostate, non-small cell lung, and breast cancers, and Actimab-A, which targets CD33-positive myeloid-derived suppressor cells in combination with checkpoint inhibitors. In hematology, Actimab-A serves as a therapy for acute myeloid leukemia and myelodysplastic syndrome, while Iomab-B and Iomab-ACT are targeted conditioning agents for bone marrow transplants and cell and gene therapies. The company addresses patients suffering from various oncologic and hematologic conditions.
The company operates in the United States and has conducted clinical trials across approximately 50 treatment centers and leading hospitals. Actinium Pharmaceuticals maintains its principal executive offices in New York, New York.
Summary of the business section of Actinium Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Actinium Pharmaceuticals, Inc.
- Founded
- 2013
- Headquarters
- New York, NY
- Address
- 100 Park Ave., 23rd Floor 10017
- Phone
- (646) 677-3870
- Website
- actiniumpharma.com
- Employees
- 25, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAS P.C, Houston, Texas
Stock & identifiers
- Ticker
- ATNM
- Exchange
- NYSE
- IPO date
- Dec 27, 2012
- Shares outstanding
- 31M, Aug 6, 2026
- Public float
- $43.66M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-30 reverse, Aug 14, 2020; 1-for-30 reverse, Aug 11, 2020; 1-for-14 reverse, Mar 29, 2013
- SEC CIK
- 1388320
- CUSIP
- 00507W206
- ISIN
- US00507W2061
- LEI
- 549300LCY1NZSXCQDT45
- EIN
- 88-0378336
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sandesh Seth | Chief Executive Officer, Director | 938,081 |
| Steffen Wilhem Heeger | Chief Medical Officer | 153,868 |
| Adeela Kamal | Chief Scientific Officer | 213,648 |
| Steve O'Loughlin | Chief Financial Officer | 35,500 |
| Richard I. Steinhart | Director | 63,116 |
| Nicholson, C. David | Director | 63,300 |
| June Sherie Almenoff | Director | 18,000 |
| Ajit Shetty | Director | 62,357 |
| Jeffrey W. Chell | Director | 61,600 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Sandesh Seth | $1.17M | -$4.50M | $581.80K | $16 | – |
| FY2023 Sandesh Seth | $4.70M | -$1.13M | $1.49M | $65 | – |
| FY2022 Sandesh Seth | $4.02M | $10.64M | $1.48M | $137 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of March 25, 2026, we had 25 full-time employees, 12 of whom have Ph.D.”
Corporate history
Events identified from SEC filings